×
About 16,938 results

ALLMedicine™ Glucagon Center

Research & Reviews  5,933 results

Revisiting the Strategies for the Pharmacological Management of Type 2 Diabetes- from G...
https://doi.org/10.1111/jdi.13726
Journal of Diabetes Investigation; Li HY

Dec 2nd, 2021 - The goals of diabetes care are to prevent complications and optimize quality of life. Based on the goals, several strategies have developed and are still evolving for the pharmacological management of type 2 diabetes. In the last decade, various n...

Glucagon-like peptide-1 receptor agonists do not decrease the risk of coronary revascul...
https://doi.org/10.1097/MCA.0000000000001111
Coronary Artery Disease; Patoulias D, Papadopoulos C et. al.

Dec 1st, 2021 - Glucagon-like peptide-1 receptor agonists do not decrease the risk of coronary revascularization in patients with type 2 diabetes.|2021|Patoulias D,Papadopoulos C,Kassimis G,Doumas M,|

A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's...
https://doi.org/10.3233/JAD-210612
Journal of Alzheimer's Disease : JAD; Lynn J, Park M et. al.

Nov 30th, 2021 - Dementias, including the type associated with Alzheimer's disease (AD), are on the rise worldwide. Similarly, type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic diseases globally. Although mechanisms and treatments are well-estab...

Insulin resistance induced by long-term sleep deprivation in rhesus macaques can be att...
https://doi.org/10.1152/ajpendo.00329.2021
American Journal of Physiology. Endocrinology and Metabol... Zhao Y, Shu Y et. al.

Nov 30th, 2021 - Long-term sleep deprivation (SD) is a bad lifestyle habit, especially among specific occupational practitioners, characterized by circadian rhythm misalignment and abnormal sleep/wake cycles. SD is closely associated with an increased risk of meta...

Active Consumption of Konjac and Konjac Products Improves Blood Glucose Control in Pati...
https://doi.org/10.1080/07315724.2021.2002739
Journal of the American College of Nutrition; Ueno H, Haraguchi N et. al.

Nov 30th, 2021 - Konjac is a food mainly consumed in Asian countries with high fiber and low energy. Although glucomannan, a component of konjac, have been used for several clinical studies, there is few reports using konjac itself. This study examined the effects...

see more →

Guidelines  3 results

Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-base...
https://doi.org/10.1016/j.kint.2020.06.024
Kidney International; de Boer IH, Caramori ML et. al.

Jul 13th, 2020 - Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeuti...

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Repor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971782
Diabetes Care; Buse JB, Wexler DJ et. al.

Dec 21st, 2019 - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials...

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the America...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245208
Diabetes Care; Davies MJ, D'Alessio DA et. al.

Oct 7th, 2018 - The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation ...

see more →

Drugs  69 results see all →

Clinicaltrials.gov  310 results

A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
https://clinicaltrials.gov/ct2/show/NCT04992312

Nov 18th, 2021 - The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years. Blood tests will be performed to check how ...

Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes
https://clinicaltrials.gov/ct2/show/NCT03258853

Nov 18th, 2021 - The current study is designed to test the feasibility of the a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults and children with cystic fibro...

Observation on Obesity Undergoing SOWI
https://clinicaltrials.gov/ct2/show/NCT05122936

Nov 17th, 2021 - Obesity is a worldwide problem to public health, with a prevalence rate of 12.4% according to recent studies. It is associated with a series of chronic non-communicable diseases, including type 2 diabetes, cardiovascular diseases, non-alcoholic fa...

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
https://clinicaltrials.gov/ct2/show/NCT04330625

Nov 17th, 2021 - REMD-477 (Volagidemab) is a human anti-glucagon receptor antibody. Its proposed mechanism of action in controlling hyperglycemia is by blocking glucagon receptor (GCGR) signaling. In this way, it increases hepatic glucose uptake, decreases hepatic...

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
https://clinicaltrials.gov/ct2/show/NCT05119179

Nov 15th, 2021 - This clinical trial will uncover new mechanisms of inter-individual responses to endogenous and exogenous glucagon-like peptide-1 (GLP-1) in Hispanics/Latinos (H/Ls) with prediabetes. The results move the management of prediabetes, type 2 diabetes...

see more →

News  454 results

Weight Loss Win for Weekly Injections of Novel Amylin Agent in Early Trial
https://www.medpagetoday.com/endocrinology/obesity/95757

Nov 18th, 2021 - The investigational long-acting amylin analogue cagrilintide (AM833) helped people with overweight or obesity, but no diabetes, shed pounds in a phase II trial. In the randomized trial, all doses of the novel once-weekly injectable treatment yield...

More STEP Data: Semaglutide Cuts Weight, Cravings, Beats Liraglutide
https://www.medscape.com/viewarticle/962728

Nov 11th, 2021 - The STEP 5 clinical trial extends favorable weight loss from 1 year out to 2 years for the glucagon-like peptide-1 (GLP-1) agonist semaglutide (Wegovy, Novo Nordisk), given as a once-weekly 2.4-mg subcutaneous injection, and some food cravings wer...

Managing Patients With HR+ MBC on PI3K Therapy
https://www.onclive.com/view/managing-patients-with-hr-mbc-on-pi3k-therapy

Nov 5th, 2021 - Joyce O’Shaughnessy, MD: I’d love to hear from everybody what your personal experience has been with alpelisib. We also want to touch on toxicity so we can weave together a little bit of your personal experience efficacy-wise—which patients, where...

'Twincretin' Beats Glargine for Diabetes in Pivotal Trial
https://www.medscape.com/viewarticle/961762

Oct 28th, 2021 - The "twincretin" tirzepatide scored another pivotal-trial win in full, published results from the multicenter SURPASS-4 trial, which compared the investigational agent to insulin glargine for treatment of type 2 diabetes. The study comprised 1,995...

Eli Lilly's Recalled Emergency Diabetes Drug Came From Plant Cited by FDA
https://www.medscape.com/viewarticle/960256

Oct 6th, 2021 - (Reuters) - A recently recalled batch of Glucagon Emergency Kits, Eli Lilly and Co's therapy for diabetic patients in crisis, was manufactured at an Indiana factory cited by U.S. health regulators this year for quality-control violations, includin...

see more →

Patient Education  6 results see all →